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Abstract
Background Long-term survival of patients with hepato-
cellular carcinoma (HCC) after liver transplantation is
affected mainly by recurrence of HCC. There is the opinion
that the chance of recurrence after 2 years post-transplan-
tation is remote, and therefore lifelong surveillance is not
justified because of limited resources. The aims of the
present study were to determine the rate of late HCC
recurrence (C2 years after transplantation) and to compare
the long-term patient survival outcomes between cases of
early recurrence (\2 years after transplantation) and late
recurrence.
Patients A total of 139 adult HCC patients having liver
transplantation during the period from July 1994 to
December 2007 were included in the analysis. The median
follow-up period was 55 months. Thirty-two patients
received deceased-donor grafts and 107 received living-
donor grafts.
Results Hepatocellular carcinoma recurrence occurred in
24 (17.3%) patients, among them 22 (86%) had living-
donor grafts and 7 (5%) developed late recurrence. Patients
in the early recurrence group and patients in the late
recurrence group had comparable demographics and dis-
ease pathology. The former group, when compared with
the latter, had significantly worse overall survival at
3 years (13.3 versus 100%) and 5 years (6.67 versus
71.4%) (log-rank test; p \ 0.001).
Conclusions Both early recurrence and late recurrence of
HCC after liver transplantation were not uncommon,
mostly detected at a subclinical stage. Regular and long-
term surveillance with imaging and blood tests is essential
for early detection.
Introduction
Hepatocellular carcinoma (HCC) is the leading cause of
death in patients with hepatitis B or C, and its incidence has
increased considerably over the past decade [1]. Among
various modalities for treating HCC and underlying cir-
rhosis, liver transplantation (LT) is the ultimate solution.
Unfortunately, HCC recurs in 10–60% of patients after LT
[2–6]. The average time for recurrence ranges between 1
and 2 years after LT [2–6]. However, there have been
limited studies on late recurrence C2 years after LT) of
HCC, and its occurrence is poorly understood. The present
study was designed to determine the rate of late HCC
recurrence and to compare the long-term patient survival
outcomes between cases of early recurrence (\2 years after
LT) and late recurrence.
Patients and methods
Data of all adult HCC patients who underwent LT, with
deceased donor or living donor, at Department of Surgery,
Queen Mary Hospital, Hong Kong, China, in the period
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from July 1994 to December 2007 were reviewed. The
strategies adopted for selection and management of
patients with known HCC for LT have been described
elsewhere [7]. In brief, only patients aged 65 years or
below with disease not amenable to partial hepatectomy
and local ablation were considered for LT. Before 2002,
the radiological Milan criteria [2] (solitary tumor up to
5 cm in size, or a maximum of 3 tumor nodules with each
no larger than 3 cm) were observed in selection of
patients. Since 2002, the tumor number and size limits
have been expanded to match the criteria of University of
California, San Francisco (UCSF criteria) [8] (solitary
tumor not exceeding 6.5 cm, or a maximum of three
tumor nodules totaling up to 8 cm in diameter with each
nodule no bigger than 4.5 cm). Tumor evaluation was
done with computed tomography of the abdomen and
thorax, in addition to radionuclide bone scan at initial
diagnosis. In recent years dual-tracer [11C-acetate and
18F-fluorodeoxyglucose (FDG)] positron emission tomog-
raphy was occasionally performed on selected patients to
exclude extrahepatic metastasis. Imaging was repeated
every 3–6 months for patients with prolonged waiting
time, and transarterial lipiodol chemoembolization was
given to patients with adequate liver reserve to contain
tumor growth. Patients whose tumors progressed to
beyond the acceptance criteria as shown by serial imaging
were excluded from transplantation. Also excluded were
patients who had major vascular invasion or extrahepatic
diseases.
All living liver graft donors must have compatible ABO
blood group, serology negative of hepatitis B surface
antigen and hepatitis C antibody, and no evidence of any
acute or chronic illness that would increase operation risk.
Computed tomography with volumetry was performed to
determine the size of the donor liver, and left-lobe graft or
right-lobe graft was decided with the principle that the graft
must be larger than 40% of the recipient’s standard liver
weight [9] as estimated according to the Urata formula
[10].
Hospital mortality was defined as death occurring during
the hospital admission for the primary operation. Patients
were followed up at the outpatient clinic weekly within the
first 3 months after operation, and afterwards every
1–3 months, depending on clinical status and results of
liver function tests. Routine blood tests, including hepatic
and renal function tests, were carried out in every follow-
up visit. Serum a-fetoprotein check, chest X-ray, and
computed tomography (or magnetic resonance imaging for
patients with impaired renal function) were performed
every 3–6 months during the first 5 years after operation.
After 5 years, imaging was done every 6 months–1 year or
when deemed indicated (e.g., serum a-fetoprotein level
showing a rising trend).
Statistical analysis
Comparison of categorical variables was performed using a
chi-square test or Fisher’s exact test where appropriate.
Nonparametric continuous variables were compared with
the Mann–Whitney U-test and presented as medians with
range. Parametric continuous variables were compared
with Student’s t-test and presented as means with standard
deviation. Survival was analyzed with the Kaplan–Meier
method, and comparison of variables was performed using
the log-rank test. All p values less than 0.05 were regarded
as statistically significant, and all p values were two-tailed.
Results
A total of 139 patients, 119 male and 20 female, were
included for analysis. Among them, 115 patients had no
recurrence of HCC, 17 patients had early recurrence, and 7
patients had late recurrence. The early recurrence group
and the late recurrence group had comparable demo-
graphics and disease pathology (Table 1). Two patients
developed very late recurrence ([5 years after LT). One of
them had recurrence in the left adrenal gland 5.2 years
after LT, and was treated with laparoscopic adrenalectomy.
She remained free of disease for 1 year until a recent
computed tomography scan revealed a 1 cm intrahepatic
recurrence, which was treated with percutaneous radiofre-
quency ablation. She has been free of disease since then.
The other patient had recurrence in the retrocaval lymph
node 6.5 years after LT. The recurrence was deemed un-
resectable because there was tumor thrombus inside the
inferior vena cava. Treatments for other patients’ recur-
rence are listed in Table 2. All surgical specimens were
sent for histopathologic examination and were confirmed to
be metastatic HCC. The early recurrence group, when
compared with the late recurrence group, had significantly
poorer overall survival (Fig. 1). The former had overall
survival at 1, 3, and 5 years at 100, 13.3, and 6.67%,
respectively, and the latter had 100, 100, and 71.4%,
respectively (Table 3). Similarly, survival after recurrence
was also poorer in the early recurrence group, although it
did not reach statistical significance (Fig. 2).
Discussion
The tumor recurrence rate in this study was 17.3% (24/
139), which is not uncommon. Late recurrence occurred in
5% (7/139) of patients; 2 patients even developed recur-
rence after 5 years of LT. All recurrences were found at a
subclinical stage, and this demonstrates the importance of
regular surveillance as early intervention may prolong
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survival. Patients with early recurrence had much worse
overall survival than those with late recurrence. More
intrahepatic recurrences were found in the early recurrence
group, whereas more extrahepatic recurrences were found
in the late recurrence group (Table 2), which is consistent
with findings of previous studies [11, 12]. This also reflects
the difference in tumor biology, but the mechanism is still
poorly understood.
Late recurrence of HCC after LT was quite common in
this study. As noted by Poon [13], a strict surveillance
program monitoring recurrence should be adopted before
any recommendation can be made with a large cohort.
After all, current evidence is suboptimal. It was showed
that viral load of hepatitis B may be an important risk
factor for late recurrence after resection [14]. However, all
the patients in this study were on some sort of antiviral
Table 1 Demographic and
pathologic data of the two
groups
LT liver transplant,
HBV hepatitis B virus,
HCV hepatitis C virus,
UCSF University of California
San Francisco
a One patient in the early
recurrence group had no viable
tumor on histopathology after
transarterial chemoembolization
Early recurrence
(n = 17)
Late recurrence
(n = 7)
p value
Sex (male:female) 17:0 6:1 0.292
Median age, years (range) 47 (40–61) 52 (41–56) 0.292
Deceased-donor LT:living-donor LT 1:16 1:6 0.507
HBV carrier 17 7
HCV carrier 0 0
HBV and HCV co-infection 0 0
Median preoperative a-fetoprotein, ng/ml
(range)
84 (4–117,850) 411 (3–975) 0.391
Pretransplant treatment
No treatment 4 3
Transarterial chemoembolization 6 2
Ethanol injection 0 0
Hepatectomy 5 2
Chemotherapy 1 0
Radiofrequency ablation 5 1
Pretransplant anti-HBV therapy
Lamivudine 13 5
Lamivudine ? adefovir 1 2
Entecavir 2 0
Lamivudine ? Tenofovir 0 0
Lamivudine ? Adefovir ? Entecavir 1 0
HBV-DNA positivity at study end point (%) 8 (47.1) 1 (14.3) 0.002
HBV mutant detected at study end point (%) 4 (23.5) 2 (28.6) 0.900
Salvage transplantation (%) 9 (52.9) 3 (42.9) 1.000
Explant pathology (no. of tumors)a 0.998
1 7 3
2 2 1
3 2 1
C4 5 2
Median largest tumor size, cm (range) 3.6 (1.5–19.5) 2.5 (1.0–7.5) 0.482
Presence of microvascular permeation (%) 11 (64.7) 3 (42.9) 0.393
TNM staging 2003 0.133
I (%) 3 (17.6) 3 (42.9)
II (%) 10 (58.8) 1 (14.3)
IIIA (%) 4 (23.5) 3 (42.9)
IIIB (%) 0 (0) 0 (0)
Within Milan criteria 7 4 0.659
Beyond Milan criteria 10 3
Within UCSF criteria 9 4 1.000
Beyond UCSF criteria 8 3
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therapy before LT surgery, and hepatitis B surface antigen
positivity was similar in the two recurrence groups. So, at
least in this study, the role of viral load might not have
been too significant in recurrence.
In Western countries, HCC is mainly caused by HCV
infection, but in our locality, HBV infection is the main
cause. Although effective treatments for HBV infection are
available, recurrence of HCC is still common. To decrease
the rate of HCC recurrence, further adjuvant treatments for
high-risk patients have to be developed.
Notoriously, HCC recurrence after LT carries very poor
prognosis in the presence of the effects of immunosup-
pression. An early report suggested that recurrent HCC
after transplantation has a more aggressive course than
recurrent HCC after resection, presumably because of
immunosuppression [15]. Nonetheless, our center adopts
an aggressive approach in managing patients with recur-
rence after LT, and treatments include resection and
Table 2 Treatments of recurrences in the two groups
Treatmenta Early recurrence
(n = 17)
Late recurrence
(n = 7)
Intrahepatic recurrence
Hepatectomy 2 0
Transarterial
chemoembolization
4 1
Radiofrequency ablation 3 1
Extrahepatic recurrence
Adrenalectomy 1 1
Lung resection 6 0
Excision of solitary peritoneal
metastasis
0 1
Excision of retrocaval lymph
node
0 1
Excision of inferior vena cava
tumor thrombus
0 1
Excision of common hepatic
artery lymph node
0 1
Chemotherapy 4 1
Radiotherapy 6 3
Interferon 3 0
Tamoxifen 0 1
Sorafenib 5 0
Xeloda 1 1
Nailing and plating of bone
metastasis
2 1
a A patient might receive more than one treatment modality
Overall survival of patients after liver transplantation
No recurrence (n=115)
Late recurrence (n=7)
Early recurrence (n=17)
All (n=139)
P=0.000*
Fig. 1 Overall survival of patients after liver transplantation
Table 3 Postoperative outcomes in the two groups
Early
recurrence
(n = 17)
Late
recurrence
(n = 7)
p value
Latest HBsAg in HBV patients 0.393
Negative 11 3
Positive 6 4
History of rejection 3 (17.6%) 0 0.611
Latest immunosuppression 0.665
FK 506 8 5
Sirolimus 7 2
FK 506 ? prednisolone 1 0
FK 506 ? sirolimus 1 0
Hospital mortality (%) 0 (0) 0 (0) a
Patient overall survival 0.001
1 year (%) 100 100
3 years (%) 13.3 100
5 years (%) 6.67 71.4
HBsAg hepatitis B surface antigen
a No HBV serology checked before death
Survival rates after recurrence
Late recurrence (n=7)
Early recurrence (n=17)
p=0.130
Fig. 2 Survival rates after recurrence
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ablation. In addition, decreasing dosage of immunosup-
pressants may help to hinder the progression of disease.
Recently, medications have been used on high-risk
patients. Sirolimus is an inhibitor of mTOR and is used as
an immunosuppressive medication on patients who are at
high risk of tumor recurrence after LT. Sorafenib (Nexavar,
Bayer HealthCare, Wayne, NJ) is a multi-kinase inhibitor
approved for the treatment of advanced HCC. A recent
study reported that the combination use of sirolimus and
sorafenib appeared to have a synergistic effect in treating
recurrent HCC after LT [16]. For the time-being, there is
no well-established protocol on the use of sorafenib at our
center. In general, it is prescribed mainly to patients with
widespread extrahepatic diseases. For patients with solitary
extrahepatic metastasis or intrahepatic recurrence, resec-
tion or ablation is the treatment of choice. Further research
on the efficacy of these medications, used solely or in
combination, will certainly contribute to the management
of recurrent HCC after LT.
In conclusion, early and late recurrences of HCC after
LT are not uncommon and can be detected at a subclinical
stage with regular monitoring. Long-term surveillance with
imaging and blood tests is essential for early detection.
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